Methicillin-resistant Staphylococcus aureus (MRSA) Reduction

AUTHORS

Travis R. Farley, Study Director

FACILITY

Microbac Laboratories, Inc.

DOWNLOAD

Full Report

Objective

To evaluate the efficacy of the NV900 on reducing methicillin-resistant Staphylococcus aureus (MRSA).

Methodology

The challenge bacteria were aerosolized using a six-jet collision nebulizer under high pressure air and introduced into the chamber with the NV900.

Summary of Results

The NV800/NV900 reduced 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) bacteria over the course of four hours.